전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
Účinnosť docetaxelu v liečbe pacientov s adenokarcinómom žalúdka
efficacy of docetaxel in the treatment of patients with gastric adenocarcinoma
마지막 업데이트: 2017-04-26
사용 빈도: 8
품질:
tabuľka 1: Úrovne znižovania dávky u pacientov s adenokarcinómom pankreasu
table 1: dose level reductions for patients with pancreatic adenocarcinoma
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
gemcitabín je indikovaný na liečbu pacientov s lokálne pokročilým alebo metastazujúcim adenokarcinómom pankreasu.
gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
마지막 업데이트: 2012-04-12
사용 빈도: 2
품질:
v tabuľke 7 sú uvedené nežiaduce účinky hodnotené u pacientov s adenokarcinómom pankreasu liečených abraxanom v kombinácii s gemcitabínom.
table 7 lists adverse reactions assessed in patients with pancreatic adenocarcinoma treated with abraxane in combination with gemcitabine.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
u pacientov s metastatickým adenokarcinómom pankreasu liečených onivyde bola pozorovaná sepsa s neutropenickou horúčkou a následným septickým šokom s fatálnym koncom.
sepsis with neutropenic fever and consequent septic shock with fatal outcome has been observed in patients with metastatic pancreatic adenocarcinoma treated with onivyde.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
veľkosť vzorky však bola malá, neexistovala žiadna signifikantná interakcia a ci bol široký a zahŕňal hr pre os celkovej populácie s adenokarcinómom.
however, the sample size was small, there was no significant interaction and the ci was wide and included the hr for os of the overall adenocarcinoma population.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
5,8 % pacientov s adenokarcinómom vstúpilo do štúdie s lokálne rekurentným štádiom ochorenia, ako bolo vyhodnotené na začiatku.
5.8 % of the adenocarcinoma patients entered the study with locally recurrent disease stage as had been evaluated at baseline.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
tabuľka 2: Úpravy dávkovania pri neutropénii a/alebo trombocytopénii na začiatku cyklu alebo počas cyklu u pacientov s adenokarcinómom pankreasu
table 2: dose modifications for neutropenia and/or thrombocytopenia at the start of a cycle or within a cycle for patients with pancreatic adenocarcinoma
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
výbor chmp poznamenal, že prínos lieku cyramza pri predĺžení života pacientov s rakovinou žalúdka alebo adenokarcinómom gastroezofageálneho spojenia bol jasne preukázaný, ak sa liek cyramza podával spolu s paklitaxelom.
the chmp noted that the benefit of cyramza in prolonging the lives of gastric and gastro-oesophageal junction cancer patients was clearly demonstrated when cyramza was given with paclitaxel.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
hnačka sa vyskytla u 43,4 % (≥ stupeň 3: 6,3 %) pacientov s adenokarcinómom v ramene s nintedanibom.
diarrhoea occurred in 43.4 % (≥ grade 3: 6.3 %) of adenocarcinoma patients in the nintedanib arm.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
taxotere v kombinácii s cisplatinou a 5-fluóruracilom sa indikuje na liečbu pacientov s metastatickým adenokarcinómom žalúdka, vrátane gastroezofageálneho spojenia, ktorí sa predtým nepodrobili chemoterapii pre metastatické ochorenie.
taxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
uskutočnilo sa multicentrické, otvorené, randomizované klinické skúšanie na vyhodnotenie bezpečnosti a účinnosti docetaxelu v liečbe pacientov s metastatickým adenokarcinómom, vrátane adenokarcinómu gastroezofageálneho spojenia, ktorí sa predtým nepodrobili chemoterapii pre metastatické ochorenie.
a multicenter, open-label, randomized trial, was conducted to evaluate the safety and efficacy of docetaxel for the treatment of patients with metastatic gastric adenocarcinoma, including
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
herceptin v kombinácii s kapecitabínom alebo 5-fluóruracilom a cisplatinou sa indikuje na liečbu dospelých pacientov s her2-pozitívnym metastatickým adenokarcinómom žalúdka alebo gastroezofágového spojenia, ktorí nedostávali protinádorovú liečbu na metastatické ochorenie.
herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro- esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Účinok tarcevy na celkové prežitie bol podobný u pacientov s východiskovým stavom výkonnosti (ecog) 2- 3 (hr = 0, 77, is 0, 6- 1, 0) alebo 0- 1 (hr = 0, 73, is 0, 6- 0, 9), u mužov (hr = 0, 76, is 0, 6- 0, 9) alebo žien (hr = 0, 80, is 0, 6- 1, 1), pacientov mladších ako 65 rokov (hr = 0, 75, is 0, 6- 0, 9) alebo starších pacientov (hr = 0, 79, is 0, 6- 1, 0), pacientov s jedným predchádzajúcim režimom (hr = 0, 76, is 0, 6- 1, 0) alebo s viac ako jedným predchádzajúcim režimom (hr = 0, 75, is 0, 6- 1, 0), u pacientov kaukazského (hr = 0, 79, is 0, 6- 1, 0) alebo ázijského etnika (hr = 0, 61, is 0, 4- 1, 0), u pacientov s adenokarcinómom (hr = 0, 71, is 0, 6- 0, 9) alebo skvamóznym bunkovým karcinómom (hr = 0, 67, is 0, 5- 0, 9), ale nie u pacientov s inými histologickými typmi (hr = 1, 04, is 0, 7- 1, 5), u pacientov s ochorením v štádiu iv pri diagnóze (hr = 0, 92, is 0, 7- 1, 2) alebo s ochorením v štádiu < iv pri diagnóze (hr = 0, 65, is 0, 5- 0, 8).
the effect of tarceva on overall survival was similar in patients with a baseline performance status (ecog) of 2-3 (hr = 0.77, ci 0.6-1.0) or 0-1 (hr = 0.73, 0.6-0.9), male (hr = 0.76, ci 0.6-0.9) or female patients (hr = 0.80, ci 0.6-1.1), patients < 65 years of age (hr = 0.75, ci 0.6-0.9) or older patients (hr = 0.79, ci 0.6-1.0), patients with one prior regimen (hr = 0.76, ci 0.6-1.0) or more than one prior regimen (hr = 0.75, ci 0.6-1.0), caucasian (hr = 0.79, ci 0.6-1.0) or asian patients (hr = 0.61, 0.4-1.0), patients with adenocarcinoma (hr = 0.71, ci 0.6-0.9) or squamous cell carcinoma (hr = 0.67, ci 0.5-0.9), but not in patients with other histologies (hr 1.04, ci 0.7-1.5), patients with stage iv disease at diagnosis (hr = 0.92, ci 0.7-1.2) or < stage iv disease at diagnosis (hr = 0.65, 0.5-0.8).
마지막 업데이트: 2012-04-12
사용 빈도: 3
품질:
경고: 보이지 않는 HTML 형식이 포함되어 있습니다